Stefan K. Barta

7.1k total citations · 2 hit papers
146 papers, 2.1k citations indexed

About

Stefan K. Barta is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Stefan K. Barta has authored 146 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 96 papers in Oncology, 88 papers in Pathology and Forensic Medicine and 34 papers in Genetics. Recurrent topics in Stefan K. Barta's work include Lymphoma Diagnosis and Treatment (88 papers), CAR-T cell therapy research (55 papers) and Chronic Lymphocytic Leukemia Research (31 papers). Stefan K. Barta is often cited by papers focused on Lymphoma Diagnosis and Treatment (88 papers), CAR-T cell therapy research (55 papers) and Chronic Lymphocytic Leukemia Research (31 papers). Stefan K. Barta collaborates with scholars based in United States, Germany and France. Stefan K. Barta's co-authors include Yang Liu, Sandra P. Susanibar-Adaniya, Carlyn Tan, Saif Abdul-Majeed, Jakub Svoboda, Ariela Noy, Joseph A. Sparano, Daniel J. Landsburg, Jeannette Y. Lee and Yasuhiro Oki and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Stefan K. Barta

129 papers receiving 2.1k citations

Hit Papers

Diffuse large B‐cell lymphoma: 2019 update on diagnosis, ... 2019 2026 2021 2023 2019 2021 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Diffuse large B‐cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment
    2019 307 citations Stefan K. Barta et al. profile →
  2. 2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management
    2021 202 citations Stefan K. Barta et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stefan K. Barta United States 23 1.1k 1.1k 439 431 341 146 2.1k
Thomas Zwingers Germany 16 1.2k 1.0× 1.0k 0.9× 386 0.9× 224 0.5× 259 0.8× 30 2.2k
Adam J. Olszewski United States 28 1.3k 1.2× 1.3k 1.2× 539 1.2× 363 0.8× 781 2.3× 212 3.1k
Bijal Shah United States 26 1.4k 1.3× 835 0.8× 649 1.5× 270 0.6× 448 1.3× 232 2.6k
Mina L. Xu United States 18 781 0.7× 580 0.5× 726 1.7× 695 1.6× 208 0.6× 78 2.2k
Sami Boussetta France 13 1.0k 0.9× 1.0k 0.9× 223 0.5× 193 0.4× 238 0.7× 46 2.0k
Daniel Wu United States 21 767 0.7× 756 0.7× 1.1k 2.4× 351 0.8× 187 0.5× 37 2.3k
Maria Christina Cox Italy 30 842 0.8× 743 0.7× 850 1.9× 430 1.0× 516 1.5× 111 2.8k
Daruka Mahadevan United States 24 634 0.6× 574 0.5× 834 1.9× 410 1.0× 680 2.0× 70 2.1k
Joachim Burman Sweden 28 814 0.7× 1.6k 1.5× 507 1.2× 686 1.6× 188 0.6× 111 2.8k

Countries citing papers authored by Stefan K. Barta

Since Specialization
Citations

This map shows the geographic impact of Stefan K. Barta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefan K. Barta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefan K. Barta more than expected).

Fields of papers citing papers by Stefan K. Barta

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefan K. Barta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefan K. Barta. The network helps show where Stefan K. Barta may publish in the future.

Co-authorship network of co-authors of Stefan K. Barta

This figure shows the co-authorship network connecting the top 25 collaborators of Stefan K. Barta. A scholar is included among the top collaborators of Stefan K. Barta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stefan K. Barta. Stefan K. Barta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nasta, Sunita D., Jakub Svoboda, Stefan K. Barta, et al.. (2025). Prolonged Neurologic Symptoms Following Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients With Large B-cell Lymphoma Treated With Chimeric Antigen Receptor-Modified T Cell Therapy. Transplantation and Cellular Therapy. 31(4). 228–235. 2 indexed citations
2.
Sussman, Jonathan, Colin Thomas, Daniel J. Landsburg, et al.. (2025). Pembrolizumab in Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome. JAMA Dermatology. 161(6). 656–656.
3.
Chong, Elise A., Sunita D. Nasta, Daniel J. Landsburg, et al.. (2024). Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma. Transplantation and Cellular Therapy. 30(7). 726.e1–726.e8. 4 indexed citations
4.
Kim, Ellen J., et al.. (2024). Immune-related adverse events associated with mogamulizumab: a comprehensive review of the literature. Expert Review of Anticancer Therapy. 24(9). 819–827. 4 indexed citations
5.
6.
Yegya‐Raman, Nikhil, Christopher M. Wright, Michael J. LaRiviere, et al.. (2023). Salvage radiotherapy for relapsed/refractory non‐Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy. Clinical and Translational Radiation Oncology. 39. 100587–100587. 4 indexed citations
7.
Tavakkoli, Montreh, Elise A. Chong, Marco Ruella, et al.. (2023). CD5 Expression in Mature T Cell Lymphoma. Blood. 142(Supplement 1). 6195–6195. 1 indexed citations
8.
Iyer, Swaminathan P., Patrick B. Johnston, & Stefan K. Barta. (2023). Pralatrexate injection combined with CHOP for treatment of PTCL: results from the Fol-CHOP dose-finding phase 1 trial. Blood Advances. 8(2). 353–364. 7 indexed citations
9.
Epperla, Narendranath, Geoffrey Shouse, Natalie S. Grover, et al.. (2023). Impact of Maintenance Rituximab Following First-Line Systemic Therapy on Outcomes in Patients with Marginal Zone Lymphoma: Real-World Evidence from 10 US Centers. Blood. 142(Supplement 1). 5147–5147.
10.
Snook, Adam E., Guido Ghilardi, Steven Yang, et al.. (2023). Senza5 TM CART5: An Autologous CD5-Deleted Anti-CD5 CART Product with Enhanced Anti-T-Cell Lymphoma Activity. Blood. 142(Supplement 1). 3462–3462. 1 indexed citations
11.
Epperla, Narendranath, Qiuhong Zhao, Tamara K. Moyo, et al.. (2023). Outcomes of marginal zone lymphoma treated with ibrutinib in the first-line setting in the United States: a real-world analysis. Blood Advances. 8(3). 549–552.
12.
Grover, Natalie S., Pallawi Torka, Marcus P. Watkins, et al.. (2023). Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort study. Blood Advances. 7(22). 6839–6843. 3 indexed citations
13.
Rastogi, Supriya, Daniel J. Lewis, Leah Cohen, et al.. (2023). Mogamulizumab Multimodality Therapy with Systemic Retinoids, Interferon, or Extracorporeal Photopheresis for Advanced Cutaneous T‐Cell Lymphoma. Dermatologic Therapy. 2023(1). 2 indexed citations
14.
Landsburg, Daniel J., Sunita D. Nasta, Jakub Svoboda, et al.. (2023). Survival Outcomes for Patients with Relapsed/ Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or Chimeric Antigen Receptor-Modified T Cells. Transplantation and Cellular Therapy. 29(8). 495–503. 3 indexed citations
15.
Wei, Wei, Zhihui Song, Wenming Xiao, et al.. (2020). A20 and RBX1 Regulate Brentuximab Vedotin Sensitivity in Hodgkin Lymphoma Models. Clinical Cancer Research. 26(15). 4093–4106. 20 indexed citations
16.
Siminoff, Laura A., Maureen Wilson‐Genderson, Stefan K. Barta, & Maria D. Thomson. (2020). Hematological cancer patient‐caregiver dyadic communication: A longitudinal examination of cancer communication concordance. Psycho-Oncology. 29(10). 1571–1578. 20 indexed citations
17.
Barta, Stefan K., Jerald Z. Gong, & Pierluigi Porcu. (2019). Brentuximab vedotin in the treatment of CD30+ PTCL. Blood. 134(26). 2339–2345. 19 indexed citations
18.
19.
Barta, Stefan K., Jeannette Y. Lee, Lawrence D. Kaplan, Ariela Noy, & Joseph A. Sparano. (2011). Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV‐associated non‐Hodgkin lymphoma. Cancer. 118(16). 3977–3983. 62 indexed citations
20.
Dierks, Thomas, Stefan K. Barta, L. Demisch, et al.. (1999). Intensity dependence of auditory evoked potentials (AEPs) as biological marker for cerebral serotonin levels: effects of tryptophan depletion in healthy subjects. Psychopharmacology. 146(1). 101–107. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas Zwingers Breakdown of academic impact, for papers by Adam J. Olszewski Breakdown of academic impact, for papers by Bijal Shah Breakdown of academic impact, for papers by Mina L. Xu Breakdown of academic impact, for papers by Sami Boussetta Breakdown of academic impact, for papers by Daniel Wu Breakdown of academic impact, for papers by Maria Christina Cox Breakdown of academic impact, for papers by Daruka Mahadevan Breakdown of academic impact, for papers by Joachim Burman
Rankless by CCL
2026